The anti-diabetics market includes drugs, which are used for treatment of diabetes mellitus and are also known as oral hypoglycemic/antihyperglycemic agents. The anti-diabetics market has grown tremendously in recent years with increasing prevalence of diabetes mellitus. Thus, systemic therapies for diabetes have become the focal point of attention due to the burgeoning diabetic population size, with diabetes affecting middle age groups and children across all income groups globally. Some of the major drivers and opportunities for growth of this market include drug combinations of several agents such as sitagliptin and metformin and other drug combinations that are in different stages of clinical and pipeline development. Increase in the prevalence of diabetes and new product launches by major pharmaceutical companies re some of the key drivers for growth in this market. In 2015, Boehringer Ingelheim GmbH launched two new drugs (Synjardy & Glyxambi)for treatment of diabetes mellitus type II. Market Analysis and Insights: Global Anti-Diabetic Drugs Market The global Anti-Diabetic Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Anti-Diabetic Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Anti-Diabetic Drugs market in terms of revenue. On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Anti-Diabetic Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Anti-Diabetic Drugs market. Global Anti-Diabetic Drugs Scope and Market Size Anti-Diabetic Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Anti-Diabetic Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027. Segment by Type Biguanides Sulfonylureas Meglitinides Thiazolidinediones Dipeptidyl Peptidase IV Inhibitors ?-Glucosidase Inhibitors Segment by Application Type I Diabetes Type II Diabetes Others By Region North America U.S. Canada Europe Germany France U.K. Italy Russia Nordic Rest of Europe Asia-Pacific China Japan South Korea Southeast Asia India Australia Rest of Asia Latin America Mexico Brazil Rest of Latin America Middle East & Africa Turkey Saudi Arabia UAE Rest of MEA By Company Astra Zeneca Boehringer Ingelheim Eli Lilly Johnson & Johnson Merck Novartis Novo Nordisk Sanofi Teva Pharmaceutical Industries
1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Anti-Diabetic Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027 1.2.2 Biguanides 1.2.3 Sulfonylureas 1.2.4 Meglitinides 1.2.5 Thiazolidinediones 1.2.6 Dipeptidyl Peptidase IV Inhibitors 1.2.7 ?-Glucosidase Inhibitors 1.3 Market by Application
